These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 2010669

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment.
    Moghadasian MH, Nguyen LB, Shefer S, Salen G, Batta AK, Frohlich JJ.
    Metabolism; 2001 Jun; 50(6):708-14. PubMed ID: 11398149
    [Abstract] [Full Text] [Related]

  • 4. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol.
    Harada LM, Carrilho AJ, Oliveira HC, Nakandakare ER, Quintão EC.
    Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1209-15. PubMed ID: 17184503
    [Abstract] [Full Text] [Related]

  • 5. Effects of 15-oxa-32-vinyl-lanost-8-ene-3 beta,32 diol on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase and low density lipoprotein receptor in rat liver.
    Ness GC, Lopez D, Chambers CM, Zhao Z, Beach DL, Ko SS, Trzaskos JM.
    Arch Biochem Biophys; 1998 Sep 15; 357(2):259-64. PubMed ID: 9735166
    [Abstract] [Full Text] [Related]

  • 6. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR, Pula KK, Alton KB, Burrier RE, Watkins RW.
    Metabolism; 2001 Oct 15; 50(10):1234-41. PubMed ID: 11586500
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antihypercholesterolemic property of naringin alters plasma and tissue lipids, cholesterol-regulating enzymes, fecal sterol and tissue morphology in rabbits.
    Jeon SM, Park YB, Choi MS.
    Clin Nutr; 2004 Oct 15; 23(5):1025-34. PubMed ID: 15380892
    [Abstract] [Full Text] [Related]

  • 9. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E, Rudling M, Ståhlberg D, Berglund L, Ewerth S, Björkhem I, Einarsson K, Angelin B.
    N Engl J Med; 1990 Jul 26; 323(4):224-8. PubMed ID: 2114543
    [Abstract] [Full Text] [Related]

  • 10. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors unmask cryptic regulatory mechanisms.
    Lopez D, Chambers CM, Ness GC.
    Arch Biochem Biophys; 1997 Jul 01; 343(1):118-22. PubMed ID: 9210653
    [Abstract] [Full Text] [Related]

  • 11. Stimulation of the proliferation of the Madin-Darby canine kidney (MDCK) epithelial cell line by high-density lipoproteins and their induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.
    Gospodarowicz D, Cohen DC, Massoglia SL.
    J Cell Physiol; 1983 Oct 01; 117(1):76-90. PubMed ID: 6352714
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of lovastatin on hypercholesterolemia in chronic renal failure.
    Subang MC, Stewart-Phillips JL, Gagnon RF.
    Adv Perit Dial; 1992 Oct 01; 8():381-4. PubMed ID: 1361828
    [Abstract] [Full Text] [Related]

  • 14. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase unmask transcriptional regulation of hepatic low-density lipoprotein receptor gene expression by dietary cholesterol.
    Lopez D, Ness GC.
    Arch Biochem Biophys; 1997 Aug 01; 344(1):215-9. PubMed ID: 9244400
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein fractions and receptors: a role for probucol?
    Bilheimer DW.
    Am J Cardiol; 1986 Jun 27; 57(16):7H-15H. PubMed ID: 3637051
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor.
    Ioriya K, Kino K, Horisawa S, Nishimura T, Muraoka M, Noguchi T, Ohashi N.
    J Cardiovasc Pharmacol; 2006 Feb 27; 47(2):322-9. PubMed ID: 16495773
    [Abstract] [Full Text] [Related]

  • 17. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in the rat ileum: effects of bile acids and lovastatin.
    Nguyen LB, Shefer S, Salen G, Ness GC, Batta A, Chowdhary IR, Paroulek E, Hauser S.
    Metabolism; 1994 Nov 27; 43(11):1446-50. PubMed ID: 7968602
    [Abstract] [Full Text] [Related]

  • 18. Hepatic cholesterol metabolism in estrogen-treated men.
    Angelin B, Olivecrona H, Reihnér E, Rudling M, Ståhlberg D, Eriksson M, Ewerth S, Henriksson P, Einarsson K.
    Gastroenterology; 1992 Nov 27; 103(5):1657-63. PubMed ID: 1426886
    [Abstract] [Full Text] [Related]

  • 19. Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects.
    Stone BG, Evans CD, Prigge WF, Duane WC, Gebhard RL.
    J Lipid Res; 1989 Dec 27; 30(12):1943-52. PubMed ID: 2621421
    [Abstract] [Full Text] [Related]

  • 20. Increase in serum and bile cholesterol and HMG-CoA reductase by lovastatin in rats.
    Yamauchi S, Linscheer WG, Beach DH.
    Am J Physiol; 1991 Apr 27; 260(4 Pt 1):G625-30. PubMed ID: 2018137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.